Abstract | OBJECTIVES: PATIENTS AND METHODS: RESULTS: Seventeen patients with ICC and 13 patients with GBC were enrolled. All patients were evaluable for safety. WHO grade 3/4 drug-related adverse events occurred in 8 patients (27%), consisting of diarrhea and leukopenia in 5 and 3 patients, respectively. One patient with diarrhea grade 4 finally succumbed to sepsis. Objective response rate was 10% (95% confidence interval, 2.1%-26.5%), with an additional 10% of patients showing stable disease. Median overall survival was 166 days and 273 days, and median progression-free survival was 84 days and 159 days for ICC and GBC, respectively. CONCLUSIONS: Fufiri is a well-tolerated regimen in patients with ICC and GBC but has only modest activity in advanced biliary tract cancer.
|
Authors | Jürgen Feisthammel, Konrad Schoppmeyer, Joachim Mössner, Manfred Schulze, Karel Caca, Marcus Wiedmann |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 30
Issue 3
Pg. 319-24
(Jun 2007)
ISSN: 1537-453X [Electronic] United States |
PMID | 17551313
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Vitamin B Complex
- Irinotecan
- Folic Acid
- Fluorouracil
- Camptothecin
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Biliary Tract Neoplasms
(drug therapy)
- Camptothecin
(analogs & derivatives, therapeutic use)
- Female
- Fluorouracil
(therapeutic use)
- Folic Acid
(therapeutic use)
- Humans
- Irinotecan
- Male
- Middle Aged
- Survival Analysis
- Vitamin B Complex
(therapeutic use)
|